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Background: Psoriasis lesions are characterized by large-scale shifts in gene expression. Mechanisms that underlie
differentially expressed genes (DEGs), however, are not completely understood. We analyzed existing datasets to
evaluate genome-wide expression in lesions from 163 psoriasis patients. Our aims were to identify mechanisms that
drive differential expression and to characterize heterogeneity among lesions in this large sample.
Results: We identified 1233 psoriasis-increased DEGs and 977 psoriasis-decreased DEGs. Increased DEGs were
attributed to keratinocyte activity (56%) and infiltration of lesions by T-cells (14%) and macrophages (11%). Decreased
DEGs, in contrast, were associated with adipose tissue (63%), epidermis (14%) and dermis (4%). KC/epidermis DEGs
were enriched for genes induced by IL-1, IL-17A and IL-20 family cytokines, and were also disproportionately associated
with AP-1 binding sites. Among all patients, 50% exhibited a heightened inflammatory signature, with increased
expression of genes expressed by T-cells, monocytes and dendritic cells. 66% of patients displayed an IFN-γ-strong
signature, with increased expression of genes induced by IFN-γ in addition to several other cytokines (e.g., IL-1, IL-17A
and TNF). We show that such differences in gene expression can be used to differentiate between etanercept
responders and non-responders.
Conclusions: Psoriasis DEGs are partly explained by shifts in the cellular composition of psoriasis lesions. Epidermal
DEGs, however, may be driven by the activity of AP-1 and cellular responses to IL-1, IL-17A and IL-20 family cytokines.
Among patients, we uncovered a range of inflammatory- and cytokine-associated gene expression patterns. Such
patterns may provide biomarkers for predicting individual responses to biologic therapy.
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Psoriasis is a chronic disease affecting 1-2% of the adult
population, with estimates rising as high as 8% in certain
geographic regions [1]. Psoriasis plaque formation is largely
driven by cytokine-mediated interactions among dendritic
cells, T-cells and keratinocytes (KCs), leading to altered dif-
ferentiation and extensive KC proliferation [2,3]. To better
understand this process, genome-wide expression profiling
has been used to identify genes and pathways altered in
psoriasis lesions as compared to normal skin [4-10]. Over
the years, the power of this approach has improved as
studies have scaled up to include samples from more* Correspondence: wswindel@umich.edu
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reproduction in any medium, provided the orpatients, increasing statistical power to generate more ro-
bust findings. Two independent microarray studies, for
instance, have now been performed using large cohorts
with more than 60 patients each [8,11]. These data have
allowed investigators to robustly identify differentially
expressed genes and extract gene lists [4-10]. However,
while individual genes with altered expression have
been identified, underlying mechanisms remain unclear.
Further work is therefore needed to understand how
expression patterns in psoriasis lesions are connected
to the inflammatory and cytokine dynamics that drive
plaque formation.
Large-scale alteration of gene expression in psoriasis
plaques is driven, in part, by differences in the compos-
ition and abundance of cell types present within lesional
and non-lesional skin [6,12]. KC proliferation, forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sequently psoriasis-increased genes include those genes
expressed at high levels in KCs [6,12]. Likewise, psoriasis
plaque formation is associated with an influx of non-
resident immune cells, including T-cells, dendritic cells,
macrophages and neutrophils [2,3], leading to the forma-
tion of dermal/epidermal inflammatory cell aggregates
[13], and thus to increased expression of genes specifically
expressed in lymphocytes and myeloid-derived cells. In
psoriasis [6], and other conditions [14,15], these tissue re-
modeling processes have been investigated using statistical
approaches applied to genome-wide expression patterns,
which identify “signature genes” associated with individual
cell types, and apply this information to identify shifts in
cellular composition and to quantify the magnitude of
these shifts. This approach, while informative, is not itself
sufficient to understand the psoriasis transcriptome, how-
ever, since altered expression may also result from the ac-
tivation or inhibition of cytokine-responsive pathways in
resident cell types [5,6,16]. In cultured KCs, for example,
stimulation with IL-17A leads to induction of β-defensins
and pro-inflammatory S100 proteins [17], and such genes
are consistently increased in psoriasis lesions [5,8-10]. In
psoriasis, such cytokine-driven transcriptional responses
of resident cells are superimposed upon shifts in cellular
composition, adding a second layer of complexity to the
transcriptome. Here again, however, statistical approaches
have proven effective, and prior work has identified “cyto-
kine activity signatures” embedded within the psoriasis
transcriptome, based upon comparison of genes altered in
psoriasis lesions with those altered in KCs stimulated by
specific cytokines in vitro [5,6,16,18].
A second important, but less well explored, aspect of
the psoriasis transcriptome is the heterogeneity observed
among lesions sampled from different patients [6,7]. Pre-
vious studies have often focused on the expression of
genes showing consistent differences between lesional
and non-lesional skin, emphasizing analysis of differen-
tially expressed genes (DEGs) [8-10]. While understand-
ing mechanisms that drive differential expression remains
important, the advent of larger datasets now permits new
questions to be addressed [6,7]. One study, for instance, has
identified two molecular sub-types of psoriasis based upon
paired lesional (PP) and non-lesional (PN) samples from 37
patients, with one group (21 patients) characterized by PP-
elevated expression of HLA-E, and the other group (16 pa-
tients) by elevated expression of genes involved in adaptive
immunity (e.g., CTLA-4, IFI30, IL4IL, PTPN2 and
SERPINB8) [7]. Another study, with 62 patients, divided pa-
tients into three sub-groups based upon scores quantifying
inflammatory infiltration by immune cell types (e.g., macro-
phages, dendritic cells and monocytes), along with two sub-
groups differing in the expression of genes activated by IL-
13 and other cytokines (e.g., IFN-α, TNF, IL-1a, IL-17A,and IFN-γ) [6]. With larger datasets, the finer-scale
characterization of these variations should improve our
ability to discern molecular sub-types. Ultimately, this may
facilitate development of expression-based biomarkers that
are biologically meaningful, but also useful for clinical ap-
plications (e.g., predicting response to biologic therapy)
[6,7].
In this study, we analyzed genome-wide expression
patterns in the involved (PP) and uninvolved (PN) skin
from 163 psoriasis patients. Our analysis combines
microarray data from three separate studies, each of
which profiled gene expression using the same oligo-
nucleotide array platform [8,11,19]. Using these data, we
identify genes differentially expressed between PP and
PN skin (i.e., DEGs), and assess whether these genes are
enriched for cytokine-responsive genes or genes specific-
ally expressed in distinct cell populations. Based upon
these results, we associate most DEGs with a specific cell
type and/or cytokine, and we have further identified
mechanisms of transcriptional regulation by testing for
association with transcription factor binding sites. Fi-
nally, we mapped the lesion-to-lesion variation associ-
ated with distinct inflammatory and cytokine signatures,
leading to the identification of molecular sub-types
among the 163 lesions. Extending these results, we show
that such heterogeneous aspects may be associated with
the response of patients to etanercept therapy.
Results
80% of genes significantly elevated in psoriasis lesions
can be explained by KC activity and infiltration by T-cells
and macrophages
We assembled expression data from three studies in which
raw data had been deposited in Gene Expression Omnibus
(GSE13355, GSE14905 and GSE30999; Affymetrix Human
Genome Plus 2.0 array; see Methods) [8,11,19]. Following
quality control analyses, pooled data included paired
lesional (PP) and non-lesional (PN) biopsies from 163
patients. For each patient, we calculated the difference
(PP – PN) in expression for each probe set on the
array. Based upon these differences, we identified 1233
differentially expressed genes (DEGs) with significantly
increased expression in psoriasis lesions (FDR < 0.05
and FC > 1.50).
We hypothesized that some PP-increased DEGs could
be explained by KC activity and increased abundance of
inflammatory cell types within lesions (e.g., T-cells and
macrophages). To assess this possibility, we assembled a
microarray database containing samples associated with
a diverse range of 24 cell types (see Methods). Using this
database, we identified genes showing a cell type-specific
expression pattern*, with expression significantly higher in
samples for one cell type, as compared to the other 23 cell
types. As expected, DEGs most strongly increased in PP
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KC-specific expression pattern, with significantly higher
expression in KCs as compared to other cell types
(Figure 1). We next tested whether the 1233 PP-
increased DEGs overlapped significantly with genes
specifically expressed in skin-associated cell types, in-
cluding resident cells (e.g., KCs, fibroblasts and adipo-
cytes) and potentially infiltrating inflammatory cells
(e.g., T-cells, monocytes, macrophages and dendritic
cells). This identified six cell types for which cell
type-specific genes were enriched among the 1233 PP-
increased DEGs, including KCs, γδ T-cells, macrophages,
epidermis, CD34+ cells and NK cells (FDR < 0.05;
Figure 2A). [*Note: By “cell type-specific” expression, we
refer to genes with quantitatively higher expression in
one specific cell type, even though such genes might have
detectable expression in multiple cell types].
What fraction of PP-increased DEGs can be explained by
the six cell types we identified? To address this question,
we evaluated each DEG individually, and assigned eachFigure 1 Cell type-specific expression of the 35 genes most strongly
(PN). The left margin lists the 35 genes most strongly elevated in PP skin r
Heatmap colors show fold-change estimates for each of 24 cell types (colu
in a given cell type (numerator), relative to its expression among the 23 ot
gene expression is significantly altered in one cell type as compared to allDEG to a cell type if the gene was specifically expressed in
that cell type (FDR < 0.05 and FC > 1.50). If a DEG could
be assigned to more than one cell type, it was preferentially
assigned to the single cell type for which cell type-specific
genes were most strongly enriched among all PP-increased
DEGs (Figure 2A). Overall, 90% of the DEGs could be
assigned to the six cell types, with most (80%) attributed
to KCs (56%), γδ T-cells (14%) and macrophages (11%)
(Figure 2B). DEGs assigned to KCs, for instance, included
SERPINB4, S100A12, TCN1 and KRT16, while those
assigned to γδ T-cells included CD3G, CD3D, IFNG and
TNIP3. Closer inspection revealed further trends among
the PP-increased DEGs. In particular, DEGs most strongly
elevated in PP skin (FC > 3) were enriched for genes highly
expressed in KCs and epidermis (Figure 2C). However,
DEGs less strongly elevated in PP skin (1.5 < FC < 3.0) were
more highly expressed in inflammatory cells, such as γδ T-
cells, macrophages and NK cells (Figure 2C).
These trends were reinforced by analysis of LCM-
dissected dermal inflammatory cells from PP skin andelevated in psoriasis lesions (PP) compared to uninvolved skin
elative to PN skin (FDR < 0.05; ranked according to PP/PN fold-change).
mns), with fold-changes estimated as the ratio of a gene’s expression
her cell types (denominator). Triangle symbols denote cases in which
other cell types (see legend).
Figure 2 Genes significantly elevated in psoriasis lesions can be explained by KC activity and infiltration of lesions by T-cells and
macrophages. (A) The 1233 PP-increased genes were analyzed to assess enrichment for genes specifically expressed in each of 24 cell types. Positive
enrichment statistics indicate that PP-increased genes were more likely to be specifically expressed in that cell type relative to 18793 non-DEGs.
Negative statistics indicate that PP-increased genes were less likely to be specifically expressed in that cell type relative to the 18793 non-DEGs. Asterisk
symbols denote significantly large or small enrichment statistics (Wilcoxon rank sum test; FDR < 0.05). (B) The 1233 PP-increased genes were each
assigned to one of the six cell types with significant and positive enrichment statistics in part (A). A gene was assigned to a cell type if it was
specifically expressed in that cell type (FDR < 0.05 and FC > 1.50). If a gene could be assigned to more than one cell type, it was assigned to the single
cell type for which enrichment was highest in part (A). The pie chart shows the proportion of 1233 PP-increased genes assigned to each cell type. The
“unexplained” category includes PP-increased genes not specifically expressed in any of the six significant cell types. (C) The 1233 PP-increased genes
were ranked according to fold-change increase in PP versus PN skin. Windows of 100 genes each were then evaluated at each point in the ranking to
assess enrichment for genes specifically expressed in a given cell type (see legend).
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We identified 609 genes elevated in LCM-dissected
dermal inflammatory cells from PP skin (relative to LCM-
dissected PN dermis; P < 0.05 and FC > 1.50). As ex-
pected, these genes were not significantly enriched for
genes specifically expressed in KCs (Additional file 1, Part
A). However, there was significant enrichment for genes
specifically expressed in the three inflammatory cell types
identified above (γδ T-cells, macrophages and NK cells)
(FDR < 0.05; Additional file 1). Additionally, there was sig-
nificant enrichment for other T-cell subsets, including
CD3+ T-cells, CD4+ T-cells and CD8+ T-cells, regulatory
T-cells and dendritic cells, suggesting that LCM may en-
hance the resolution for detection of expression shifts aris-
ing from the formation of immune cell aggregates in PP
skin (Additional file 1, Part A). Using the same criteria
stated above, we could assign a cell type to more than 90%
of the 609 genes elevated in LCM-dissected dermal in-
flammatory cells from PP skin (Additional file 1, Part B).80% of genes decreased in psoriasis lesions are
specifically expressed in subcutaneous adipose tissue,
dermis and epidermis
Our analysis of PP and PN samples from 163 patients
identified 977 PP-decreased DEGs (FDR < 0.05 and FC <
0.67). Among genes most strongly decreased in PP skin
(e.g., BTC, WIF1 and THRSP), most were weakly expre-
ssed in myeloid-derived cell types, but did show specific
expression in epidermis (Additional file 2). Among all 977
PP-decreased DEGs, we identified significant enrichment
for genes specifically expressed in eight cell types (FDR <
0.05; Figure 3). Most of these were skin-resident cell types
and in fact PP-decreased DEGs were most enriched for
genes expressed at high levels in subcutaneous adipose tis-
sue, dermis and epidermis (Figure 3A). To determine the
proportion of PP-decreased DEGs that may be accounted
for by these cell types, PP-decreased DEGs were inspected
one-by-one, and each was assigned to one of the eight sig-
nificant cell types (Figure 3A). Overall, 90% of PP-
Figure 3 80% of genes decreased in psoriasis lesions are specifically expressed in subcutaneous adipose tissue, dermis and epidermis.
(A) The 977 PP-decreased genes were analyzed to assess enrichment for genes specifically expressed in each of 24 cell types. Asterisk symbols
denote significantly large or small enrichment statistics (Wilcoxon rank sum test; FDR < 0.05). (B) The 977 PP-decreased genes were each
assigned to one of the eight cell types with significant and positive enrichment statistics in part (A). A gene was assigned to a cell type if it was
specifically expressed in that cell type (FDR < 0.05 and FC > 1.50). If a gene could be assigned to more than one cell type, it was assigned to the
single cell type for which enrichment was highest in part (A). The pie chart shows the proportion of 977 PP-decreased genes assigned to each
cell type. (C) The 977 PP-decreased genes were ranked according to fold-change decrease in PP versus PN skin. Windows of 100 genes each
were evaluated at each point in the ranking to assess enrichment for genes specifically expressed in a given cell type (see legend).
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eight cell types (FDR < 0.05 and FC > 1.50), with 80%
assigned to subcutaneous adipose tissue (63%), epider-
mis (14%) or dermis (4%) (Figure 3B). Further inspec-
tion revealed that, although DEGs most strongly
decreased in PP skin (FC < 0.50) tended to be expressed
in epidermis (Figure 3C), those DEGs with moderately
decreased expression (0.50 < FC < 0.66) were more
commonly expressed at high levels in subcutaneous adi-
pose tissue or dermis/fibroblasts (Figure 3C).
Epidermal genes elevated in psoriasis lesions overlap
best with genes induced by IL-1, IL-17 and IL-20 family
cytokines in cultured KCs
Of 1233 PP-increased DEGs, we designated 709 as “epi-
dermal”, based upon their high expression in KCs or epi-
dermis as compared to 22 other cell types in our analysis
(Figure 2A and 2B). Potentially, increased expression of
these genes may be driven by the altered cytokine environ-
ment within psoriasis lesions [5,6,16]. We thus compiled
data from 42 experiments in which genome-wide expres-
sion was evaluated in cultured monolayer KCs (or 3-Dreconstituted epidermis) following cytokine treatment
(Additional file 3). As expected, among the top 30 epider-
mal PP-increased DEGs, most were increased by at least
one cytokine treatment, with several DEGs increased by
multiple cytokines (e.g., SERPINB4, S100A12, SPRR2C,
DEFB4A, PI3; Additional file 4).
We screened the 42 experiments to determine which
cytokine treatments induced a set of genes that over-
lapped best with the 709 epidermal PP-increased DEGs.
In parallel, we evaluated how well genes induced in each
experiment overlapped with 900 genes significantly ele-
vated in LCM-isolated epidermis from psoriasis lesions
as compared to LCM-isolated epidermis from normal
skin (FDR < 0.05 and FC > 1.50) [13]. We expected ana-
lysis of both gene sets to yield similar results, and in-
deed, there was good agreement, with significant and
corresponding results obtained for 35 of the 42 experi-
ments (Figure 4). Overall, three groups of cytokines in-
duced a gene set that overlapped best with the 709
epidermal PP-increased DEGs, including the IL-1, IL-17
and IL-20 families (Figure 4). Of the 13 top-ranked ex-
periments, nearly all (12 of 13) involved experiments in
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groups. Genes induced by IL-1, IL-17 and IL-20 family cy-
tokines in vitro thus bear the closest resemblance to epi-
dermal DEGs elevated in PP skin.
Among the 709 epidermal PP-increased DEGs, 143
(20%) were not significantly altered in any of the 35 ex-
periments for which induced/repressed genes over-
lapped significantly with the 709 DEGs (e.g., AKR1B10,
C10orf99 and WDR66; Additional file 5). Such non-
responsive DEGs may be increased in PP skin due to al-
teration in the KC differentiation program, or otherwise,
may be elevated due to expansion of the KC compart-
ment. Most DEGs (566 of 709), however, were signifi-
cantly altered by cytokine treatment in at least one
of the 35 significant experiments, and overall, weFigure 4 Epidermal genes elevated in psoriasis lesions overlap best w
cultured KCs. In part (A), 709 epidermal PP-increased DEGs were evaluate
in each of 42 cytokine experiments. In each experiment, KCs or reconstitute
identify induced genes. Experiments using HaCaT KCs are indicated with a
epidermis are indicated by a double asterisk (**). All other experiments util
concentration (per mL), the length of time cells were treated, and the Gen
accessed. Positive statistics indicate that the 709 genes were disproportion
were disproportionately repressed. A single asterisk symbol denotes signific
asterisk symbols denote significance according to both the Wilcoxon rank
was repeated based upon 900 genes significantly elevated in LCM-dissecte
uninvolved skin (FDR < 0.05 & FC > 1.50). In the bottom margin, red labels
and (B) (FDR < 0.05). Blue labels denote experiments with significantly negattributed the largest number of DEGs to induction by
TNF + IFN-γ (174 DEGs), IL-1β (104 DEGs) and IL-
17A (79 DEGs) (Additional file 5).Epidermal genes decreased in psoriasis lesions overlap
best with genes repressed by IL-20 family cytokines in
cultured KCs
DEGs most strongly decreased in psoriasis (FC < 0.50)
were enriched for genes with an epidermis-specific
expression pattern (Figure 3C), and overall, we classified
134 of the 977 PP-decreased DEGs as epidermal
(Figure 3B). For some of these, expression was repressed
in vitro following cytokine treatment of KCs or
reconstituted epidermis (e.g., KRT77, C5orf46 and PLLP;ith genes induced by IL-1, IL-17, and IL-20 family cytokines in
d to determine if they were disproportionately increased or decreased
d epidermis was treated with cytokines and microarrays were used to
single asterisk symbol (*), while experiments using 3-D reconstituted
ized primary monolayer KC cultures. Labels list the cytokine used, the
e Expression Omnibus accession under which raw data can be
ately induced, while negative statistics indicate that the 709 genes
ance according to the Wilcoxon rank sum test (FDR < 0.05), while two
sum test and Fisher’s Exact Test (FDR < 0.05). In part (B), the analysis
d lesional epidermis as compared to LCM-dissected epidermis from
denote experiments with significantly positive statistics in both (A)
ative statistics in both (A) and (B) (FDR < 0.05).
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ments (Additional file 3) to determine which repressed
a set of genes that overlapped best with the 134 epider-
mal PP-decreased genes. In parallel, we evaluated how
well genes repressed in each experiment overlapped
with 876 genes significantly decreased in LCM-isolated
epidermis from PP skin as compared to LCM-isolated
epidermis from PN skin (FDR < 0.05 and FC < 0.67)
[13]. We identified 10 experiments for which cytokine-
repressed genes overlapped significantly with both sets
of PP-decreased genes (Additional file 7). For two
of these, cells were treated with IL-1β or IL-17A (Add-
itional file 6), consistent with our findings for PP-
increased genes (Figure 4). The strongest trends, how-
ever, were observed for cells treated with IL-10 family
cytokines, including all three cytokines from the IL-20
family (IL-24, IL-19 and IL-20; Additional file 7). These
results show that epidermal genes decreased in PP skin
are most similar in composition to genes repressed by
IL-10/IL-20 family cytokines in vitro. Overall, 80 of the
134 DEGs (60%) were significantly repressed in at least
one of the 10 significant experiments, and we attributed
more than half of these (46 DEGs) to repression by IL-
22 (e.g., KRT77, IL37 and FABP7; see Additional file 8).
Enrichment of AP-1 binding sites among psoriasis-
increased genes and evidence for activation of an
IL-17A → AP-1 pathway
Our analysis uncovered 709 epidermal PP-increased DEGs
(Figure 2), which were also enriched for genes induced by
IL-1, IL-17 and IL-20 family cytokines (Figure 4). We hy-
pothesized that some DEGs would be targeted by tran-
scription factors (TFs) belonging to cytokine-responsive
pathways. To address this possibility, we generated a motif
dictionary with 1209 binding sites for known TFs or
DNA-binding complexes, and we screened these sites to
determine which were most enriched in 2 KB regions up-
stream of the 709 PP-increased DEGs (see Methods).
We identified 27 sites enriched among the 709 DEGs,
including 9 associated with AP-1 (FDR < 0.05; Figure 5).
To confirm this trend, we repeated the analysis starting
with 900 genes elevated in LCM-dissected epidermis
(Additional file 9). Based on this gene set, we did not
identify sites significant at an FDR threshold of 0.05.
However, 5 of the 25 sites most enriched among the 900
genes were associated with the AP-1 complex (P ≤
0.014; FDR ≤ 0.49) (Additional file 9). Further analysis
revealed that genes encoding AP-1 components were
differentially expressed in psoriasis lesions (Additional
file 10). Among the 163 patients, there was significantly
increased expression of JUNB, FOSL1 and FOSB in PP
skin, along with significantly decreased expression of
JUND, FOSL2 and FOS (Additional file 10, Part A). Ex-
pression of JUNB, FOSL1 and FOSL2, moreover, wassignificantly elevated in LCM-dissected epidermis from
PP skin (Additional file 10, Part B), while expression of
JUNB and FOSL2 was also elevated in LCM-dissected
dermis from PP skin (Additional file 10, Part C).
We next analyzed the 27 significant sites to determine
if they were also enriched in 2 KB regions upstream of
cytokine-induced genes (Figure 5). Not surprisingly, an
NF-κB site was enriched in regions upstream of the 709
epidermal PP-increased DEGs, as well as in regions up-
stream of genes induced by IL-1- and IL-20-family cyto-
kines, IL-17A, IFN-γ and TNF (Figure 5). Interestingly,
however, among the 9 AP-1 sites enriched in regions up-
stream of PP-increased genes, each was also enriched in
regions upstream of genes induced by IL-17A, and this
result was replicated in 2-3 independent experiments
(GSE12109, GSE24767 and GSE36287; Figure 5). These
results are consistent with activation of an IL-17A →
AP-1 pathway in PP skin.
Psoriasis lesions from 163 patients can be divided into
two sub-groups based upon inflammatory gene
expression patterns (strong inflammation: 89/163; weak
inflammation: 74/163)
Gene expression patterns vary in direction and magnitude
among lesions from different psoriasis patients, potentially
reflecting distinct molecular-level sub-types [6,7]. For the
163 patients, we calculated signatures corresponding to in-
flammatory and skin-resident cell types, where the value
of each signature is equal to the weighted average of fold-
changes (PP/PN) among the 250 genes most specifically
expressed in that cell type. Consistent with our analysis of
DEGs (Figure 2), lesions from nearly all patients (≥ 89%)
were associated with significantly large γδ T-cell and KC
signatures (Figure 6). Other inflammatory signatures were
less consistent among patients (Figure 6). Using cluster
analysis, we identified 91 patients (56%) with a strong in-
flammatory signature, characterized by heightened expres-
sion of genes specifically expressed in CD3+ T-cells, CD4+
T-cells, CD8+ T-cells, macrophages, dendritic cells, mono-
cytes, neutrophils, NK cells and B cells (Figure 6). The
remaining 72 patients (44%) were associated with a weak
inflammatory signature, with reduced expression of genes
specifically expressed in these cell types (Figure 6).
Psoriasis lesions from 163 patients can be divided into two
sub-groups based upon the expression of cytokine-induced
genes (IFN-γ-strong: 104/163; IFN-γ-weak: 59/163)
We next calculated signature scores based upon genes in-
duced in each of 42 cytokine experiments (Additional file
3), where the value of each score was equal to the
weighted average of fold-changes estimated for the top
250 cytokine-induced genes (Figure 7). Signature scores
calculated for several cytokines, including IL-1α and IL-
17A, were significantly elevated in nearly every patient (≥
Figure 5 Transcription factor binding sites enriched in 2KB regions upstream of 709 epidermal PP-increased DEGs. We identified 709
epidermal PP-increased DEGs (FDR < 0.05 and FC > 1.50). For these genes, we scanned regions 2 KB upstream from the transcription start site for
matches to 1209 transcription factor binding sites (see Methods). 27 binding sites were significantly enriched among the 709 genes (Z > 0 and FDR <
0.05; left margin). For these motifs (left margin), labels indicate the consensus binding site along with identifier information from the source database
(UniPROBE, Jaspar or TRANSFAC). Magenta labels denote motifs recognized by the AP-1 complex. For each site, we tested whether its frequency was
significantly elevated in upstream regions of genes induced by cytokines in each of 42 experiments (P < 0.05 and FC > 1.50). Heatmap colors show Z
statistics from these analyses, where positive values indicate enrichment of a site in regions upstream of cytokine-induced genes, while negative values
denote underrepresentation of a site in regions upstream of cytokine-induced genes. Significantly positive or negative Z statistics are denoted by
triangle symbols (see legend). Values in the bottom margin list enrichment statistics that assess whether the 709 PP-increased DEGs are
disproportionately elevated or repressed in the cytokine experiment (see Figure 4A). Red labels denote significantly positive statistics, indicating that
the 709 PP-increased DEGs are disproportionately induced in a given cytokine experiment (Wilcoxon rank sum test and Fisher’s Exact Test; FDR < 0.05).
Blue labels denote significantly negative statistics, indicating that the 709 PP-increased DEGs are disproportionately repressed in an experiment
(Wilcoxon rank sum test and Fisher’s Exact Test; FDR < 0.05).
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varied, particularly with respect to IFN-γ, IL-1α, IL-17A,
IL-22, IL-36β, IL-36γ and TNF (Figure 7). Using cluster
analysis, we identified 104 patients (64%) with heightened
scores for these cytokines, corresponding to elevated
expression of cytokine-induced genes (Figure 7). The
remaining 59 patients (36%) were associated with weaker
scores and lower expression of cytokine-induced genes
(Figure 7). We refer to these groups as IFN-γ-strong and
IFN-γ-weak, respectively, since the distinction between
groups was especially strong with respect to the five IFN-γ
signatures included in our analysis (Figure 7). Notably,patients in the IFN-γ-weak group also tended to exhibit
weak inflammatory patterns -- 63% those with IFN-γ-weak
signatures were assigned to the weak inflammatory group
(cf., 44% of all patients belonged to the weak inflammation
group).
Lesions obtained at baseline from etanercept responders
show increased expression of TNF-induced genes and
genes specifically expressed in CD4+ T-cells
Etanercept is an anti-TNF drug that can effectively re-
solve psoriasis, but not all patients show strong improve-
ment while the condition of some may actually worsen
Figure 6 Psoriasis lesions from 163 patients can be divided into two subgroups based upon inflammatory gene expression patterns
(strong inflammation: 91/163; weak inflammation: 72/163). For each cell population, we identified 250 “signature genes” most specifically
expressed in that cell population relative to all other cell types. For each patient, a signature score was calculated as the weighted average of
fold-changes (PP/PN) among these 250 signature genes (weighted arithmetic mean). Weighted averages were calculated by assigning greatest
weight to the top-ranked gene most specifically expressed in a given cell type, with weights declining between the top-ranked and 250th-ranked
gene. Values in the bottom margin indicate the proportion of patients with significantly large (red) or small (blue) signature scores (P < 0.05).
Significance was evaluated by comparing fold-changes (PP/PN) of the 250 signature genes to those of all other genes represented on the array
(Wilcoxon rank sum test). Patients were clustered according to signature scores using complete linkage and the Euclidean distance metric. Group
assignments were made based upon whether a patient’s scores approximated a strong or weak pattern of inflammation (see legend).
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spect to inflammatory and cytokine signatures (Figures 6
and 7), we evaluated whether similar metrics could distin-
guish between etanercept responders and non-responders.
For this purpose, we used data from a previous microarray
study of biopsies (PP and PN) from patients prior to
etanercept treatment, including biopsies from 11 etanercept
responders and 4 non-responders [21]. For each of 24 cell
types, signatures were calculated based upon the top N
genes most specifically expressed in that cell type, where
the value of N was identified by searching for values that
maximized separation between responders and non-
responders (3 ≤ N ≤ 5000; Additional file 11, Part A). Like-
wise, for each of 42 cytokine experiments, signatures were
calculated based upon the top N cytokine-induced orcytokine-repressed genes, where the value of N was chosen
using the same search criteria (3 ≤ N ≤ 5000; Additional file
11, Parts B and C).
Etanercept responders had significantly higher inflam-
matory signatures, including those calculated for CD3+ T-
cells, CD4+ T-cells and B cells (P < 0.05; Additional file
11, Part A). PP skin from responders also had significantly
higher expression of genes induced by IL-17C, IL-26d, IL-
36b, TGF-α and TNF, with lower expression of genes in-
duced by IL-4 + IL-13 (P < 0.05; Additional file 11, Part
B). In addition, the expression of genes repressed by IL-
1α, IL-13, IL-36a, IFN-γ and IL-4 + IL-13 was higher in
responders, while the expression of genes repressed by IL-
17A and IL-17C was lower (P < 0.05; Additional file 11,
Part C). Combination of multiple signatures improved
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To illustrate, we mapped patients onto the bivariate space
formed by TNF-induced and CD4+ T-cell signatures
(Figure 8). Among 163 patients, signature scores ranged in
value, with some individuals showing no elevation of
TNF-induced genes or genes specifically expressed by
CD4+ T-cells (Figure 8A and 8B). Only a subset of this
variation was observed among the 11 etanercept re-
sponders and 4 non-responders (Figure 8C). However,
when mapped onto the bivariate signature space (TNF-in-
duced and CD4+ T-cell signature), there was no overlap
between responders and non-responders, with clear separ-
ation between the centroids calculated for these two
groups (dashed boxes, Figure 8C). We could thereforeFigure 7 Psoriasis lesions from 163 patients can be divided into two
(IFN-γ-strong: 104/163; IFN-γ-weak: 59/163). Signature scores were calc
induced in each of 42 cytokine experiments (top margin). Signature scores
among the 250 most strongly induced genes (weighted arithmetic mean).
weights declining between the top-ranked and 250th-ranked gene. Values
signature scores were significantly large (red) or small (blue). Significance w
genes to those of all other genes represented on the array (Wilcoxon rank
complete linkage and the Euclidean distance metric. Group assignments w
strong or weak pattern of IFN-γ activity (see legend).define two distinct regions that completely distinguished
the 4 non-responders from the 11 responders (Figure 8C).
Discussion
Psoriasis lesions arise from complex interactions among
infiltrating and resident immune cells, local skin cells,
and a network of cytokines, which together create a pro-
inflammatory microenvironment that promotes KC pro-
liferation. This working model of psoriasis pathogenesis
is consistent with prior microarray studies, all of which
have shown increased expression of inflammatory and
cytokine-related genes in lesional skin [4-10]. While
many differentially expressed genes (DEGs) have been
identified within psoriasis lesions, however, underlyingsubgroups based upon the expression of cytokine-induced genes
ulated for each patient based upon the 250 genes most strongly
were calculated as the weighted average of fold-changes (PP/PN)
The greatest weight was assigned to the top-ranked gene, with
in the bottom margin indicate the proportion of patients for which
as evaluated by comparing fold-changes (PP/PN) of the 250 signature
sum test). Patients were clustered according to signature scores using
ere made based upon whether a patient’s scores approximated a
Figure 8 Signatures calculated from TNF-induced genes and genes specifically expressed in CD4+ T-cells can differentiate between
etanercept responders (n = 11) and non-responders (n = 4). We identified TNF and CD4+ T-cell signatures that differentiate between
etanercept responders and non-responders, based upon paired lesional (PP) and non-lesional (PN) samples obtained at baseline prior to
etanercept treatment (Additional file 11). The TNF signature is calculated as the weighted average of fold-changes (PP/PN) of 6 genes induced by
treatment of KCs with TNF (10 ng/mL) for 24 hours (GSE36287; Additional file 11, Part B), while the CD4+ T-cell signature is calculated as the
weighted average of fold-changes (PP/PN) of 7 genes specifically expressed in CD4+ T-cells (Additional file 11, Part A). Parts (A) and (B) show the
distribution of signature scores among 163 patients. In part (C), signature scores from 11 etanercept responders and 4 non-responders are
plotted. Dotted squares outline the bivariate mean for each group (± 1 standard error along each axis). The dark region (lower left) outlines a
proposed decision boundary for classification of patients as etanercept non-responders.
Swindell et al. BMC Genomics 2013, 14:527 Page 11 of 20
http://www.biomedcentral.com/1471-2164/14/527mechanisms remain unclear in most cases. In this study,
therefore, we robustly identified DEGs based upon a large
sample (n = 163) and performed targeted analyses to bet-
ter understand why each DEG is differentially expressed.
Our findings show that psoriasis DEGs can be explained
in part by shifts in the cellular composition of psoriasis le-
sions (e.g., KCs and inflammatory cells), and in part by the
response of KCs to cytokines, particularly those from the
IL-1, IL-17 and IL-20 families. At the same time, among
all patients, we uncovered fine-scale differences in the
magnitude of inflammatory cell infiltration (56% strong
versus 44% weak) and cytokine activity (64% IFN-γ-strong
versus 36% IFN-γ-weak). While we could assign mecha-
nisms to explain many psoriasis DEGs, therefore, the rela-
tive influence of such mechanisms on gene expression
may also vary among lesions. We propose that such inter-
patient differences can provide the basis for development
of expression-based biomarkers, which might prove useful
for predicting individual response to biologic therapies.
Psoriasis lesions and normal human skin consist of a
complex mixture of cell types, but key features of lesional
skin are an increased presence of inflammatory cells, along
with expansion and activation of the resident KC popula-
tion [22]. For such contexts, we and other investigatorshave analyzed expression data with the aim of dissecting
out the contribution of distinct cell types to observed dif-
ferences in gene expression between two treatments (e.g.,
lesional versus non-lesional skin) [6,12,14,15,23-25]. In the
present study, our findings indicate that PP-increased
DEGs are driven largely by KC activity, including expan-
sion of the KC population in PP skin and the response of
KCs to an altered cytokine environment. A fraction of PP-
increased DEGs, moreover, could be explained by an in-
flux of inflammatory cells (e.g., γδ T-cells, macrophages
and NK cells) (Figures 2 and 4). Interestingly, properties of
PP-decreased DEGs contrasted with those of the increased
DEGs, since decreased DEGs were commonly expressed
by resident cells, including subcutaneous adipose tissue
and dermis (Figure 3). We propose that four factors may
contribute to this trend. (i) First, in RNA isolates from PP
skin, increased proportional contribution of epidermis-
derived RNA would necessarily decrease the proportional
contribution of other skin cell types. (ii) Second, in one
study (GSE13355; 57/163 patients), PN samples were
obtained from the buttock/upper thigh region, which
tends to have greater subcutaneous adipose tissue and der-
mal thickness compared to regions where PP samples may
often be obtained (e.g., extensor aspects of the extremities)
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may be down-regulated in epidermal cells from PP skin
[4], and this effect may underlie altered phospholipid abun-
dance in PP skin [30-32]. (iv) Fourth, repressed gene ex-
pression may be more easily observed in non-KC skin
cells, since abundance of such cell types and their gene
products are not, in contrast to KCs, markedly elevated in
PP skin. Each of these factors (i) – (iv) would favor de-
creased expression of adipose- and/or dermis-expressed
genes in PP skin (Figure 3). To discriminate among these
possibilities, further studies are needed, and along these
lines we expect that mRNA profiling of specific cell popu-
lations will be most informative (e.g., using flow cytometry
or laser capture microdissection) [13].
Psoriasis is understood to be a T-cell-mediated disease
and treatments that block interactions between T-cells and
antigen presenting cells have demonstrated clinical efficacy
[33]. We found that genes specifically expressed in γδ T-
cells were better represented among psoriasis-increased
DEGs than those genes specifically expressed in other T-
cell subsets. This was the case not only in our analysis of
bulk skin biopsies (Figure 1), but also of LCM-dissected in-
flammatory cells from lesional dermis (Additional file 1).
This result was obtained largely because genes specifically
expressed in γδ T-cells were more consistently elevated in
psoriasis lesions (Figure 6). We detected significant γδ T-
cell signatures in 95% of psoriasis patients, including those
from the weak and strong inflammatory groups (Figure 6).
In contrast, significant signatures for other T-cell subsets
(CD4+, CD8+, natural killer, regulatory) were detected in
only 6 – 54% of patients, and most of these patients were
from the strong inflammatory group (Figure 6). As a result,
genes specifically expressed in other T-cells subsets (CD4+,
CD8+, natural killer, regulatory) were not enriched among
DEGs, which included only those genes with consistent
trends among the 163 patients (Figure 1). In agreement
with these findings, previous IHC studies have confirmed
increased abundance of γδ T-cells in lesions from psoriasis
patients [34-36]. In human skin, absolute numbers of γδ T-
cells are modest relative to αβ T-cells [35,37], although this
may differ in mouse skin, in which γδ T-cells are estimated
to constitute 90% of epidermal T-cells (i.e., many of which
are dendritic epidermal T-cells) [38]. Nevertheless, the
potential importance of γδ T-cells to psoriasis pathophysi-
ology has been supported by reports demonstrating IL-
17A production by γδ T-cells within lesions [34,39,40], by
the association between reduced abundance of γδ T-cells
in the blood and severity of psoriasis [36], and by the res-
toration of γδ T-cell numbers in the blood following suc-
cessful treatment of psoriasis with systemic therapies [36].
Cytokines mediate the inflammatory reactions that
sustain KC proliferation, and TNF, IL-12/23, and IL-17A
have each been effectively targeted by biologic therapies
[41-44]. We compared epidermal PP-increased DEGs togenes induced or repressed by cytokines across a panel
of 42 in vitro experiments, where each experiment in-
volved treatment of KCs or reconstituted epidermis with
a cytokine or cytokine combination. This allowed us to
perform an unbiased screen to assess which in vitro
cytokine expression responses overlapped best with epi-
dermal DEGs, providing indication of which cytokine
treatments generate the most “psoriasis-like” expression
profile in KCs [16,18]. In some respects, the strongest
evidence from our study supports the IL-20 family cyto-
kines as drivers of differential gene expression in psoria-
sis (i.e., IL-19, IL-20 and IL-24). Genes induced by IL-19,
IL-20 and IL-24 overlapped significantly with epidermal
genes elevated in PP skin (Figure 4), while conversely,
genes repressed by IL-19, IL-20 and IL-24 overlapped
significantly with epidermal genes decreased in PP skin
(Additional file 7). The transcriptional effects of IL-20
family cytokines, therefore, were associated with both in-
creased and decreased expression in psoriasis lesions.
Corresponding trends were observed for each of the
three cytokines (IL-19, IL-20 and IL-24), consistent with
the observation that each cytokine signals through the
same IL-20R1/IL-20R2 receptor complex [45]. Although
the importance of IL-20 family cytokines in plaque for-
mation is not completely understood, mRNA and pro-
tein levels of IL19, IL20 and IL24 are significantly
elevated in psoriatic epidermis [46]. Data from mice sug-
gests that this elevation can augment epidermal hyper-
plasia, since overexpression of either IL-20 or IL-24 (but
not IL-19) elicits a psoriasis-like phenotype [47,48].
Ultimately, events that drive psoriasis plaque formation
depend upon activation of a cytokine network, which fea-
tures interactions among cytokines from multiple families
[49]. Along these lines, our findings also support IL-17A
and IL-1 (IL-1α/IL-1β) as drivers of increased and
decreased DEGs in psoriatic epidermis (Figure 4 and
Additional file 7). IL-17A signatures from disparate studies
were repeatedly associated with psoriasis DEGs, particu-
larly the PP-increased DEGs (Figure 4). Additionally, of
the 42 cytokine treatments screened, genes induced by IL-
1α were most strongly enriched among the increased
DEGs, while genes repressed by IL-1α were most strongly
enriched among decreased DEGs (Figure 4 and Additional
file 7). This overlap between IL-1-responsive genes and
psoriasis DEGs is consistent with prior work and may re-
flect the contribution of innate immune responses to the
psoriasis transcriptome [16]. Whereas the importance of
IL-17A to pathogenesis has now been convincingly dem-
onstrated by successful treatment of patients with IL-17A
antibodies [41,50], treatments targeting IL-1 receptor have
shown efficacy only for pustular psoriasis, but not plaque
psoriasis [51]. Nevertheless, IL-1α potently induces the ex-
pression of IL-19, IL-20 and IL-24 in KCs [52,53], drives
differentiation of Th17 cells [54], and is required for
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These effects of IL-1β connect together several of the cy-
tokines (and cell types) that were best supported in our
study. We therefore speculate that, while the role of IL-1β
in psoriasis remains unclear, its activity may nonetheless
reinforce activation of the cytokine network within psoria-
sis lesions.
Cytokines initiate signaling cascades by binding to KC
receptors, ultimately leading to the activation or repres-
sion of transcription factors (TFs) that coordinate gene ex-
pression responses. We screened a dictionary of 1209 TF
binding sites to determine which were most strongly
enriched in regions 2 KB upstream of genes with signifi-
cantly altered expression in psoriasis lesions. Among
epidermal PP-increased DEGs, we identified nine AP-1
binding sites significantly enriched in 2 KB upstream re-
gions (Figure 5). Additionally, in bulk skin biopsies and in
LCM-dissected epidermis, expression of genes encoding
AP-1 components was significantly altered (e.g., JUNB,
FOSL1 and FOS; Additional file 10) [55,56]. These same
AP-1 sites, moreover, were similarly enriched in upstream
regions of genes induced by IL-17A in KC cultures (also
IFN-γ, TNF, IL-20, IL-22 and IL-24; see Figure 5). These
results implicate AP-1 as a possible mediator of cytokine-
stimulated gene expression in psoriasis lesions, and high-
light IL-17A as one potential coordinator of AP-1 activity.
In psoriasis lesions, the significance of AP-1 is not yet
clear, although AP-1 DNA binding as measured by elec-
trophoretic mobility shift assay is substantially reduced
[57]. This attenuation of AP-1 activity could contribute to
abnormal KC differentiation, since AP-1 family member
genes are differentially expressed in epidermal layers and
at different stages of differentiation [58], while expression
of a dominant negative form of c-Jun inhibits AP-1 bind-
ing in KCs and blocks KC differentiation [59-61]. Further-
more, in mice, double knockout of JunB and c-Jun leads
to a skin phenotype with altered KC differentiation, which
was suggested to mimic some features of human psoriasis
[62,63]. These findings, in combination with our own re-
sults, point to AP-1 as a downstream effector of IL-17A
(and potentially other cytokines), and support a role for
AP-1 in the abnormal KC differentiation characteristically
seen in psoriasis lesions.
Psoriasis lesions have characteristic histological features
and appear macroscopically similar, but gene expression
analyses have also identified sub-groupings among lesions
from different individuals [6,7]. Consistent with this, our
findings highlight differences in the activation status of in-
flammatory and cytokine networks in lesions from differ-
ent patients (Figures 6 and 7). To some degree, we expect
that such differences will be associated with early or late
stages of plaque development, differences in anatomical
location (e.g., trunk versus extremity), or the specific re-
gion of a plaque that is sampled (e.g., edge versus center)[6]. On the other hand, the developmental context for
each psoriasis lesion is patient-specific and likely shaped
by an integration of genetic (e.g., HLA-C genotype, etc.)
and environmental signals (e.g., diet, smoking status, sun
exposure). Consistent with this idea, we found that inflam-
matory and cytokine signatures, calculated from baseline
biopsies prior to treatment, could differentiate between
etanercept responders (n = 11) and non-responders (n =
4) (Figure 8 and Additional file 11). Etanercept responders,
for instance, showed elevated expression of TNF-induced
genes as well as genes specifically expressed in CD4+ T-
cells (Figure 8). This suggests that variation in gene
expression signatures at least partly reflects clinically rele-
vant differences between individuals, potentially due to as-
sociation with genetic factors that partially determine
responses to anti-TNF therapy [64,65]. In future work,
therefore, we expect that expression-based signatures,
representing inflammatory cell infiltration and cytokine
activity, can be integrated with genetic information to cre-
ate multivariate models that effectively forecast treatment
outcomes on an individual basis. This should improve our
understanding of factors that underlie treatment responses
while also providing a tool that will inform the clinical de-
cision of which type of antipsoriatic therapy should be
administered.
Conclusions
Psoriasis lesions are characterized by large-scale shifts in
gene expression, but mechanisms underlying these trends
are not completely understood. In this study, we analyzed
expression patterns in lesions from a large cohort (n = 163
patients) to identify mechanisms driving differentially
expressed genes (DEGs). We assigned a candidate cell type
for 90% of increased and decreased DEGs, and showed
that most increased DEGs can be explained by KC activity
and inflammatory cell infiltration (e.g., T-cells and macro-
phages). Moreover, DEGs expressed highly in epidermis
were associated with AP-1 binding sites and were heavily
enriched for cytokine-induced genes (e.g., IL-1β, IL-17A
and the IL-20 family). We identified sub-groups among
the 163 patients based upon signature scores reflecting in-
flammatory cell infiltration (strong inflammation: 56%;
weak inflammation: 44%) and cytokine activity (IFN-γ-
strong: 64%; IFN-γ-weak: 36%). Using these signature
scores, it was possible to differentiate between etanercept
responders (n = 11) and non-responders (n = 4). Overall,
this work advances an analytic framework that can be ap-
plied to interpret gene expression in psoriasis or any other
inflammatory skin disease. These findings also illustrate
the range of gene expression patterns associated with
chronic plaque psoriasis, and provide justification for
further work exploring the use of expression-based sig-
natures for prediction of treatment outcomes with anti-
TNF therapy.
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Ethics statement
Procedures were conducted according to the Declaration
of Helsinki principles. Informed written consent was
obtained from human subjects under protocols approved
by the University of Michigan institutional review board
(HUM00037994).
Gene expression datasets
We analyzed paired lesional (PP) and non-lesional (PN)
samples from three studies in which gene expression was
evaluated using Affymetrix Human Genome Plus 2.0 ar-
rays (GSE13355, GSE14905 and GSE30999) [8,11,19]. In
addition to these studies, three other datasets with PP and
PN samples have been deposited in Gene Expression
Omnibus as of October 2012 (GSE2737, GSE6710 and
GSE26866). We did not include these data in our analyses,
however, because they were generated using early-
generation Affymetrix microarray platforms (Human Gen-
ome U95A Array, Human Genome U95 Version 2, Human
Genome U133A Array, Human Genome U133A 2.0), with
features corresponding to only a limited fraction of known
human genes (60% or less). In each of the three included
studies (GSE13355, GSE14905 and GSE30999), PP samples
were obtained from either the trunk or upper/lower ex-
tremities using 4 – 6 mm skin punch biopsies. For at least
two of the studies (GSE13355 and GSE30999), PP biopsies
were preferentially obtained from the central region of
plaques, although in some cases a center could not be
clearly discerned due to an irregularly shaped border
[8,11]. PN biopsies were always obtained from uninvolved
skin with macroscopically normal appearance, but the
studies differed with regard to the location of the non-
lesional PN biopsy. For GSE14905 and GSE30999, PN bi-
opsies were obtained from an anatomical region similar to
that of the PP skin biopsy (e.g., arm, leg or trunk) [8,19]. In
contrast, for GSE13355, PN biopsies were always obtained
from the sun-protected buttock or upper thigh region, irre-
spective of the PP biopsy sampling site [11].
Preprocessing and normalization
CEL files for the three included studies (GSE13355,
GSE14905 and GSE30999) were downloaded from Gene
Expression Omnibus and Affymetrix quality control (QC)
metrics were calculated for each file. These metrics in-
cluded percentage of probe sets with signals detected
above background (percent present), global RNA degrad-
ation score, average background, intensity scale factor, and
four measures derived from the fitting of probe-level
models (RLE median, RLE IQR, NUSE median and NUSE
IQR) [66,67]. Samples from each dataset were also clus-
tered to identify potential outliers.
Additional file 12 provides an overview of the prepro-
cessing and filtering procedures. GSE13355 consisted ofPP and PN samples from 58 patients with chronic
plaque psoriasis [11]. We removed one subject because
the PN sample (GSM337287) had high scores on mul-
tiple QC metrics (RLE IQR, NUSE median and NUSE
IQR). The GSE13355 data had been collected in three
separate batches, corresponding to samples processed in
2005, 2006 and 2007, respectively. However, since the
paired PP and PN samples for all subjects belonged to
the same batch and were processed simultaneously, it
was not necessary to adjust for this effect, and we in-
stead normalized data from each batch independently
(and calculated PP – PN differences within each batch).
GSE14905 consisted of PP and PN samples from 27 pa-
tients with chronic plaque psoriasis [19]. We removed
one subject because the PP sample (GSM372350) was an
outlier in cluster analyses, had a high RNA degradation
score, low percentage of probe sets called present, and
high scores on other QC metrics (intensity scale factor,
RLE median, RLE IQR, NUSE median and NUSE IQR).
GSE30999 consisted of PP and PN samples from 81 pa-
tients with moderate-to-severe chronic plaque psoriasis
[8]. We removed one subject because the PN sample
(GSM768062) was an outlier in cluster analyses and had
a low percentage of probe sets called present, with high
scores on multiple QC metrics (intensity scale factor,
RLE median, RLE IQR, NUSE median and NUSE IQR).
After QC filtering, the combined dataset (GSE13355,
GSE14905 and GSE30999) included PP and PN samples
from 163 patients. Data from GSE14905 and GSE30999
were normalized separately using the robust multi chip
average (RMA) method [68]. The three batches from
GSE13355 were normalized separately using RMA (see
above). The Affymetrix Human Genome Plus 2.0 array
includes 54675 probe sets that collectively target 20026
human genes, with the expression of most genes assayed
by multiple probe sets [69]. To limit redundancy in our
analyses, we a priori chose a single probe set to analyze
for each of the 20026 human genes. In choosing the rep-
resentative probe set, we preferentially chose those
expected to hybridize specifically with cRNA associated
with the targeted gene (i.e., excluding probe sets
containing “_x_” or “_s_” in the Affymetrix identifier). If
there remained multiple probe sets available for a given
gene after applying this criterion, the representative
probe set was chosen as the probe set with the highest
absolute expression level on average among the 326 PP
and PN samples included in our analysis.
Identification of differentially expressed genes in PP skin
versus PN skin
To identify genes differentially expressed between PP and
PN samples, the PP – PN difference in RMA expression
score was calculated for each probe set and each patient.
A linear model was then fit to these differences to identify
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was significantly different from zero (n = 163). Among the
20026 genes represented on the Human Genome Plus 2.0
array platform, we excluded 1233 that were not signifi-
cantly expressed above background in any of the 326 PP
and PN samples [70]. For the remaining 18793 genes, raw
p-values were calculated based upon the empirical Bayes
approach and moderated t-statistics implemented in
Bioconductor’s limma package [71]. To control the pro-
portion of falsely rejected null hypotheses among all
18793 tests (i.e., false discovery rate), raw p-values were
adjusted using the Benjamini-Hochberg method [72]. For
analysis of LCM-dissected samples (Figure 4; GSE26866;
Affymetrix Human Genome U133A 2.0 array), the same
procedures were followed; however, the array platform in-
cluded probe sets representing only 12711 human genes,
of which we excluded 2060 not significantly expressed
above background in any of the 37 Affymetrix U133A 2.0
array samples included in our study (i.e., GSE11903 and
GSE26866) [13,70].
Gene set enrichment statistics
In Figures 2A, 2C, 3A, 3C and 4, we report rank-based
gene set enrichment statistics. In each case, statistics as-
sess whether genes belonging to a foreground gene set
are non-randomly distributed with respect to an inde-
pendently generated gene ranking [73]. Under the null
hypothesis of random association, enrichment statistics
are distributed on the [-0.50, 0.50] interval [73]. Positive
statistics indicate that genes belonging to the foreground
gene set are disproportionately assigned high ranks, while
negative statistics indicate that genes belonging to the
foreground gene set are disproportionately assigned low
ranks. Statistics are proportional to the Wilcoxon Rank
Sum test statistic, but can be geometrically interpreted as
the difference between two area under the curve (AUC)
metrics, based upon “detection rate” curves generated by
plotting cumulative percent overlap of a gene set [0,1]
relative to gene rank in the reference gene list [73]. In par-
ticular, the statistic is calculated as the difference AUCFG -
AUCBG, where AUCFG is the area under the AUC obtained
for the foreground gene set, and AUCBG is the AUC statis-
tic obtained for the background gene set (usually ≈ 0.50).
In our analyses, the foreground gene set is the set of PP-
increased (Figures 2 and 4) or PP-decreased genes
(Figure 3). The background gene set is the set of all genes
measured in both experiments being compared, minus
those genes belonging to the foreground gene set. For each
statistic, p-values were calculated directly from the standard
normal distribution (see equation 8 from Philippakis et al.
[73]). For evaluating the overlap between PP-increased or
PP-decreased DEGs and cytokine-responsive genes, Fisher’s
Exact Test was used as a secondary significance criterion
(Figure 4 and Additional file 7). In these cases, significantoverlap was indicated by a significantly positive enrich-
ment statistic (FDR < 0.05 by Wilcoxon Rank Sum Test)
and significant overlap between DEGs and those genes in-
duced in each cytokine experiment (FDR < 0.05 by Fisher’s
Exact Test; cytokine-induced genes defined as those with
FC > 1.50 with P < 0.05). Alternatively, significant overlap
was indicated by a significantly negative enrichment statis-
tic (FDR < 0.05 by Wilcoxon Rank Sum Test) and signifi-
cant overlap between DEGs and those genes repressed in
each cytokine experiment (FDR < 0.05 by Fisher’s Exact
Test; cytokine-repressed genes defined as those with FC <
0.67 with P < 0.05).
Definition and identification of cell type-specific genes
Among PP-increased and PP-decreased genes, we identi-
fied trends related to cell type-specific expression
(Figures 1, 2 and 3), and we have calculated signature
scores for 163 patients based the expression of “signature
genes” specifically expressed in each of 24 cell types
(Figures 6 and 7). Throughout the paper, the phrase “cell-
type specific” expression is used to denote a gene, or set of
genes, for which expression in a given cell type is distin-
guishably higher than expression in the 23 other cell types
evaluated (based upon a two-sample comparison and test
for differential expression; see below). This pattern in-
cludes genes for which expression can be detected in mul-
tiple cell types, provided that expression is higher in one
cell type relative to all others. The pattern excludes genes
expressed at similarly high levels in multiple cell types,
since in such cases a gene’s expression cannot be consid-
ered diagnostic of a particular cell type. To identify such
genes, we constructed a database with 687 microarray
samples, where each sample had been generated using the
Affymetrix Human Genome Plus 2.0 array platform.
As an initial step, we searched Gene Expression Omni-
bus and identified 4145 microarray samples associated
with 24 cell types of interest. On average, we identified
173 samples per cell type, with a minimum of 4 (eosino-
phil and dermis) and a maximum of 799 (CD138+ plasma
cell). For 13 of the 24 cell types, more than 40 microarray
samples had been identified in our comprehensive screen
of Gene Expression Omnibus. In these cases, we identified
a minimal set of 40 samples that were most archetypal of
all samples identified. To choose these 40 samples, we first
used RMA to normalize all samples identified for the cell
type. For each sample, we then calculated the average
Euclidian distance between that sample and all other sam-
ples, which allowed us to identify the 40 samples for which
this Euclidean distance was minimized. These 40 samples
we chosen as exemplars for the cell type and were thus in-
cluded in our final database of 687 samples.
After we identified the 687 samples, CEL files for all
687 samples were jointly normalized using RMA. As
noted above, the Affymetrix Human Genome Plus 2.0
Swindell et al. BMC Genomics 2013, 14:527 Page 16 of 20
http://www.biomedcentral.com/1471-2164/14/527array includes 54675 probe sets collectively targeting
20026 human genes. In our analyses, we chose a single
representative probe set for each human gene, and for
consistency, we used the same probe sets selected based
upon the criteria stated above. To identify genes with
cell type-specific expression, a two-sample comparison
was made between those samples associated with a
given cell type and all other samples in the database.
For each cell type, this comparison was performed
for each gene and p-values were generated using the
empirical Bayes approach and moderated t-statistics
implemented in Bioconductor’s limma package [71]. In
Figure 6, this procedure was used to identify the 250
signature genes, by selecting those genes with lowest p-
values and for which expression was increased in the
cell type of interest relative to all other cell types (FC >
1; also see section below on signature score calculation).
Likewise, in Figures 2A, 2C, 3A and 3C, this procedure
was followed to generate the p-values used to rank all
genes according to evidence for cell type-specific ex-
pression. Genes with FC > 1 were ranked ascendingly by
p-values, followed by genes with FC < 1, which were
ranked descendingly by p-values. After ranking genes
in this fashion, we evaluated whether a set of DEGs (PP-
increased or PP-decreased) was disproportionately as-
signed higher ranks using enrichment statistics and the
Wilcoxon rank sum test [73] (see above section on gene
set enrichment statistics).Identification of cytokine-responsive genes
Cytokine-responsive genes were identified based upon 42
experiments in which cultured KCs or reconstituted epi-
dermis had been treated with cytokines (Additional file 3).
Raw data from each experiment is available from Gene
Expression Omnibus (GSE9120, GSE25400, GSE2737,
GSE36287, GSE12109, GSE24767, GSE32620, GSE1132,
GSE440, GSE8531, GSE7661, GSE2489, GSE36387,
GSE17892, GSE32975, GSE20706 and GSE20297). For ex-
periments that evaluated expression using Affymetrix
platforms, raw data were downloaded and normalized
using RMA. For all other platforms, we used normalized
data available in GEO series matrix files. Differential ex-
pression between cytokine-treated and untreated con-
trol cells was evaluated using the empirical Bayes
approach and moderated t-statistics as implemented in
Bioconductor’s limma package [71]. For most array plat-
forms, multiple probes were available to measure ex-
pression for a given human gene. To limit redundancy,
only a single probe was analyzed as a representative of
each human gene. For each experiment, this representa-
tive probe was chosen as the one with the lowest p-
value from differential expression analysis comparing
cytokine-treated cells with untreated control cells.Calculation of signature scores
Signature scores were calculated as the weighted average of
fold-changes (PP/PN) among cytokine-responsive genes
(Figure 7) or genes specifically expressed in a given cell
type (Figure 6). For each signature, a set of N ranked genes
was defined and signature scores were calculated using the
weighted arithmetic mean of PP/PN fold-changes (R func-
tion “weighted.mean”). Calculations were performed using
log2-transformed fold-changes, although in our results we
have reported signature scores on an untransformed scale
(Figures 6, 7 and 8). The weight of each gene was equal to
the square root of its rank, with the top-ranked gene
assigned a weight of N1/2, the next-ranked gene assigned a
weight of (N-1)1/2, and so on, with the last-ranked gene
assigned a weight of 11/2. In Figure 6, the top-ranked signa-
ture genes were those with the highest fold-change expres-
sion difference (x/y), where x is the average expression in a
given cell type, and y is the average expression of the gene
in the other 23 cell types evaluated (see Figure 1). In
Figure 7, top-ranked signature genes were those with the
highest fold-change induction following cytokine treatment
(treated/control; see Additional files 4 and 6). In all cases,
the N signature genes were identified by first selecting the
1.5N genes with lowest p-value, where p-values were gener-
ated from differential expression analyses identifying genes
with cell type-specific expression (Figure 6) or genes in-
duced by cytokine treatment (Figure 7). These 1.5N genes
were then sorted descendingly according to fold-change,
and the top N genes with highest fold-change were selected
as the signature genes. In Additional file 11, the same pro-
cedures were followed to identify N signature genes, except
gene weights were assigned based upon rankings deter-
mined either by p-values or fold-change estimates, depend-
ing upon which approach led to better separation between
etanercept responders and non-responders.
Motif analyses
We screened 1209 transcription factor (TF) binding site
motifs to evaluate whether such motifs are enriched
among epidermal PP-increased DEGs (Figure 5). These
1209 non-redundant motifs were derived from the Jaspar
[74], UniPROBE [75] and TRANSFAC [76] databases, as
described in a recent research report [77]. Regions 2KB
upstream of human genes were scanned for matches to
the 1209 binding sites. Sequences were obtained from
Bioconductor (BSgenome.Hsapiens.UCSC.hg19) with co-
ordinates for each gene defined based upon UCSC
refGene files (hg19). Assembly gaps, repetitive DNA and
coding regions were masked for all genome scans. Motif
matches were identified based upon position weight matri-
ces (PWMs), with a match identified only for those loci
for which the PWM matching score was greater than 80%
of the maximum matching score for that PWM matrix
[15,77,78].
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sets and tested whether any motifs were differentially
abundant in the regions upstream of genes belonging to
each set. In Figure 5, the FG set included 709 PP-
increased genes specifically expressed in KCs or epidermis,
and the BG set included the 18084 other genes included
in our analysis (Affymetrix Human Genome Plus 2.0
array). In Additional file 9, the FG gene set included 900
genes elevated in LCM-dissected epidermis from lesional
skin relative to LCM-dissected epidermis from normal
skin, and the BG set included the 9751 other genes in-
cluded in our analysis and represented on the array plat-
form (Affymetrix Human Genome U133A 2.0 array). A
semiparametric generalized additive logistic model (GAM)
was used to test whether abundance of each motif differed
between genes in the FG and BG sets [77,79]. In GAM
models, the response variable was an indicator with value
equal to 1 if a gene belonged to the FG set and a value of
0 if a gene belonged to the BG set. Each GAM model in-
cluded two predictor variables, including log-transformed
length of upstream sequence scanned for a given gene (x1;
non-parametric term with cubic spline smoothing) and
the number of motif sites detected within the upstream se-
quence (x2; parametric term without smoothing) [77]. The
association between motif frequency and gene set mem-
bership was evaluated based upon the coefficient estimate
associated with x2. Separate models were fit for all 1209
motifs and p-values were calculated for each motif by
comparing Z statistics to the standard normal distribution
[77]. Raw p-values were adjusted to control the false
discovery rate by applying the Benjamini-Hochberg
correction [72].Additional files
Additional file 1: Genes significantly elevated in dermal
inflammatory cells from PP skin are specifically expressed in NK
cells, macrophages, dendritic cells, B cells, monocytes and multiple
T-cell subsets. Gene expression was compared between LCM-dissected
dermal inflammatory cells from PP skin and LCM-dissected dermis from
uninvolved skin (n = 3 patients; data from GEO accession GSE26866).
Based on this comparison, we identified 609 genes with significantly
elevated expression in dermal inflammatory cells from PP skin (P < 0.05
and FC > 1.50). The analysis shown in Figure 2 was performed starting
with these 609 genes.
Additional file 2: Cell type-specific expression of the 35 genes most
strongly decreased in psoriasis lesions (PP) relative to uninvolved
skin (PN). The left margin lists the 35 genes most strongly decreased in
PP skin relative to PN skin (FDR < 0.05; ranked according to PP/PN fold-
change). Heatmap colors show fold-change estimates for each of 24 cell
types (columns), with fold-changes estimated as the ratio of a gene’s
expression in a given cell type (numerator), relative to its expression
among the 23 other cell types (denominator). Triangle symbols denote
cases in which gene expression is significantly altered in one cell type as
compared to all other cell types (see legend).
Additional file 3: List of 42 cytokine experiments (primary
monolayer KC cultures, HaCaT KCs or 3-D reconstituted epidermis).
The table lists experiments in which gene expression responses wereevaluated in cytokine-treated cells. The label for each experiment indicates
the cytokine used, the concentration (per mL), the length of time cells were
treated, and the Gene Expression Omnibus accession under which raw data
can be accessed. The third column lists the microarray platform used to
evaluate gene expression in each experiment and the corresponding Gene
Expression Omnibus platform identification number. Further details on each
experiment are available from Gene Expression Omnibus or the reference
listed in the final column.
Additional file 4: Cytokine responses of the 30 epidermal genes
most strongly increased in psoriasis lesions (PP) relative to
uninvolved skin (PN). The left margin lists the 30 epidermal genes most
strongly increased in PP skin relative to PN skin (FDR < 0.05; ranked
according to PP/PN fold-change). Heatmap colors show the expression
response of each gene across 42 cytokine experiments (top margin). In
each experiment, KCs or 3-D reconstituted epidermis was treated with
cytokines and microarrays were used to measure changes in gene
expression. Experiments using HaCaT KCs are indicated with a single
asterisk symbol (*), while experiments using reconstituted epidermis are
indicated by a double asterisk (**). All other experiments utilized primary
monolayer KC cultures. Labels list the cytokine used, the concentration
(per mL), the length of time cells were treated, and the Gene Expression
Omnibus accession under which raw data can be accessed.
Additional file 5: 80% of epidermal PP-increased DEGs can be
explained as gene expression responses of KCs to cytokine
stimulation. We identified 709 epidermal PP-increased genes (Figure 2)
and showed that these genes were disproportionately induced or repressed
in 35 experiments in which KCs (or reconstituted epidermis) had been
treated with cytokines (Figure 4). We assigned each DEG to one of these 35
experiments, depending upon whether the DEG was significantly induced
or repressed (P < 0.05; also FC > 1.5 for experiments with red labels, or FC <
0.67 for experiments with blue labels). DEGs were preferentially assigned to
the experiment for which induced or repressed genes overlapped most
significantly with the complete set of 709 epidermal PP-increased genes
(Wilcoxon Rank Sum Test; Figure 4). The chart shows the number of DEGs
assigned to each experiment, where the “non-responsive” category includes
those DEGs not significantly altered in any of the 35 experiments. In the left
margin, red labels denote those experiments for which induced genes
overlapped significantly with the 709 epidermal PP-increased DEGs, while
blue labels denote those experiments for which repressed genes
overlapped significantly with the 709 DEGs (see Figure 4).
Additional file 6: Cytokine responses of the 30 epidermal genes
most strongly decreased in psoriasis lesions (PP) relative to
uninvolved skin (PN). The left margin lists the 30 epidermal genes most
strongly decreased in PP skin relative to PN skin (FDR < 0.05; ranked
according to PP/PN fold-change). Heatmap colors show the expression
response of each gene across 42 cytokine experiments (top margin). In each
experiment, KCs or 3-D reconstituted epidermis was treated with cytokines
and microarrays were used to measure changes in gene expression.
Experiments using HaCaT KCs are indicated with a single asterisk symbol (*),
while experiments using 3-D reconstituted epidermis are indicated by a
double asterisk (**). All other experiments utilized primary monolayer KC
cultures. Labels list the cytokine used, the concentration (per mL), the length
of time cells were treated, and the Gene Expression Omnibus accession
under which raw data can be accessed.
Additional file 7: Epidermal genes decreased in psoriasis lesions
overlap best with genes repressed by IL-10/IL-20 family cytokines in
cultured KCs. The analysis shown in Figure 4 was repeated based upon
(A) 134 epidermal PP-decreased DEGs (FDR < 0.05 & FC > 1.50) and (B)
876 genes decreased in LCM-dissected PP epidermis relative to LCM-
dissected epidermis from uninvolved skin (FDR < 0.05 & FC < 0.67).
Additional file 8: 60% of epidermal PP-decreased DEGs can be
explained as gene expression responses of KCs to cytokine
stimulation. We identified 135 epidermal PP-decreased genes (Figure 3)
and showed that these genes were disproportionately repressed in 10
experiments in which KCs (or reconstituted epidermis) had been treated
with cytokines (Additional file 7). We assigned each DEG to one of these
10 experiments, depending upon whether the DEG was significantly
repressed (P < 0.05 and FC < 0.67). DEGs were preferentially assigned to
the experiment for which induced or repressed genes overlapped most
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(Wilcoxon Rank Sum Test; Additional file 7). The chart shows the number
of DEGs assigned to each experiment, where the “non-responsive”
category includes those DEGs not significantly repressed in any of the 10
experiments. For two experiments (IL-20/GSE7216 and TNF/GSE2489),
none of the DEGs met our assignment criteria and thus only 8 of the 10
experiments are shown in the Figure.
Additional file 9: Transcription factor binding sites most enriched
in 2KB regions upstream of 900 genes elevated in LCM-dissected PP
epidermis from psoriasis lesions. The analysis shown in Figure 5 was
repeated starting with 900 genes elevated in LCM-dissected epidermis from
psoriasis lesions (compared to LCM-dissected epidermis from normal skin; FDR
< 0.05 and FC > 1.50). The left margin lists the top 25 motifs most strongly
enriched in 2KB regions upstream of the 900 genes (P ≤ 0.014 and FDR ≤
0.49). Values in the bottom margin list statistics calculated for each cytokine
experiment, which assess whether the 900 genes are disproportionately
elevated or repressed in a given cytokine experiment (see Figure 4B). Magenta
labels denote motifs recognized by the AP-1 complex.
Additional file 10: Genes encoding components of the AP-1
complex are differentially expressed between lesional (PP) and
uninvolved skin (PN). (A) Fold-changes (PP/PN) for genes encoding
components of the AP-1 complex were evaluated in 163 patients. Grey
boxes outline the middle 50% of fold-change estimates for each gene. (B)
Expression of AP-1 component genes was evaluated in LCM-dissected
epidermis from PP skin and LCM-dissected epidermis from PN skin (n = 3).
(C) Expression of AP-1 component genes was evaluated in LCM-dissected
dermis from PP skin and LCM-dissected dermis from PN skin (n = 3). In (B)
and (C), asterisk symbols denote genes with significantly altered expression
(P < 0.05). In (A) – (C), red labels denote genes with significantly elevated
expression in lesional skin, while blue labels denote genes with significantly
decreased expression in lesional skin (P < 0.05).
Additional file 11: Identification of inflammatory and cytokine
signatures that distinguish etanercept responders from non-
responders. (A) For each cell population, signature scores were
calculated as the weighted average of fold-changes (PP/PN) among the
top N cell type-specific genes (weighted arithmetic mean). The value of N
is listed in the top margin for each cell type, and was chosen by
searching for values (3 ≤ N ≤ 5000) that maximized separation between
responders and non-responders (i.e., minimized the p-value obtained
from a two-sample t-test). In signature calculations, genes were weighted
according to the square root of their rank (see Methods). Genes were
ranked either by p-values generated from the test for cell type-specific
expression (asterisk; top margin), or were ranked by the fold-change ratio
of a gene’s expression in a given cell type relative to the 23 other cell
types (no asterisk; top margin). The ranking approach used for a given
threshold was the one leading to better separation between responders
and non-responders. Red labels indicate cell populations for which
signature scores of responders were at least marginally higher than those
of non-responders (P < 0.10; two-sample t-test). Conversely, blue labels
denote cell types for which signature scores of non-responders were at
least marginally higher than those of responders (P < 0.10; two-sample
t-test). Italicized labels denote cases in which signature scores for
responders and non-responders differed significantly (P < 0.05). In parts
(B) and (C), the same analyses were performed, except signature scores
were calculated based upon (B) the N genes most strongly induced in
each of 42 cytokine experiments or (C) the N genes most strongly
repressed in each of 42 cytokine experiments.
Additional file 12: Overview of data processing steps leading to
detection of differentially expressed genes. Paired lesional (PP) and
uninvolved (PN) microarray samples generated using the same platform
(Affymetrix Human Genome Plus 2.0 array) were obtained from each of
three studies (GSE13355, GSE14905 and GSE30999). Following quality
control (QC) filtering, CEL files from each study were normalized using
robust multichip average (RMA). Samples from GSE13355 were collected
in three batches and each batch was normalized separately. Paired PP –
PN differences were next calculated for all genes within each dataset,
and these differences were subsequently pooled. For each gene, this
yielded PP – PN expression differences from 163 patients. We removed
from consideration 1233 genes not significantly expressed abovebackground in any of the PP and PN samples. For the remaining 18793
genes, we tested whether the mean PP – PN expression difference (log2
scale) was significantly different from zero (moderated t-test). This led to
the identification of 1233 PP-increased DEGs (FDR < 0.05 and FC > 1.50)
and 977 PP-decreased DEGs (FDR < 0.05 and FC < 0.67).
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